Arcellx stock jumps 78% on Gilead’s $7.8 billion buyout — deal terms, risks and next catalyst
Arcellx shares jumped 77.6% to $113.84 after Gilead Sciences agreed to buy the company for $115 per share in cash plus a contingent value right tied to anito-cel sales. The deal came as U.S. stocks fell on new 15% global tariffs announced by President Trump. Gilead shares slipped 0.6%. Investors are watching the FDA’s Dec. 23, 2026 review deadline for anito-cel, a CAR-T therapy for multiple myeloma.